Cedilla tops off series B with additional $25M to test drugs in mesothelioma, certain breast cancers
Cedilla Therapeutics, an oncology biotech founded by a former Editas executive, has snagged an additional $25 million to bring two small-molecule oncology programs into human trials. The financing ...
Bayer BAYRY has announced an exclusive license agreement with Cedilla Therapeutics to jointly develop and commercialize the latter’s CyclinE1/CDK2 complex inhibitors for targeted oncogenic treatments.
BERLIN & BOSTON--(BUSINESS WIRE)--Bayer and Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced an exclusive license agreement to develop and ...
Aspiring to understand and exploit protein stability, Cedilla Therapeutics has launched with $56.2 million in its first formal round of funding from Third Rock Ventures. Cambridge, Mass.-based Cedilla ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results